Abstracts tagged "meta-analysis"

Abstract Number: 1240 • ACR Convergence 2022
A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy for the Diagnosis of Cardiac Sarcoidosis
Omar Abialmouna¹, Mohamad Kalot², Mohamad Hamade³, Ronak Bahuva², Ariba Hasmi², Aamir Ahmed², Zachary Brumberger², Jordan Troy², Ali Choaib⁴, Ronak Bharucha², Ross Moyer², Karin Provost², Brian Page² and Umesh Sharma², ¹University at Buffalo, North Tonawanda, NY, ²University at Buffalo, Buffalo, NY, ³University of Miami, Miami, FL, ⁴Lebanese American University, Beirut, Lebanon
Background/Purpose: Autopsy reports for patients with sarcoidosis have suggested that up to 25% have cardiac involvement, mostly undiagnosed. Given the limited diagnostic accuracy of endomyocardial…
Abstract Number: 1578 • ACR Convergence 2022
Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis
Francis Lao¹, Cal Robinson², Megan Schlorff¹, Joycelynn Ewusie³, KAREN BEATTIE¹ and Michelle Batthish¹, ¹McMaster University, Hamilton, ON, Canada, ²The Hospital for Sick Children, Hamilton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose: Kawasaki Disease (KD) is a common childhood vasculitis. Coronary artery aneurysms (CAAs) develop in approximately 25% of untreated KD patients. However, there is limited…
Abstract Number: 1766 • ACR Convergence 2022
COVID-19 Cutaneous and Systemic Manifestations Among Race: A Systematic Review and Meta-Analysis
Angie El-Said¹, Areeb Ahmad², Massimo Valenti³, Neel K. Shah¹, Susana Soto¹ and Shazia Beg⁴, ¹University of Central Florida College of Medicine, Orlando, FL, ²University of Central Florida, Orlando, FL, ³Sapienza University of Rome, School of Medicine, Rome, Italy, ⁴UCF, Orlando, FL
Background/Purpose: Although various systemic and dermatologic manifestations associated with COVID-19 have been reported in the literature, investigations of how these manifestations vary by race remain…
Abstract Number: 1770 • ACR Convergence 2022
Prevalence and Incidence of Depression in Patients with Rheumatoid Arthritis: A Systematic Review
John E Oghene¹, Griffin Reed², Ian Saldanha³, Pooja Reddy⁴, Ahmed Elshazly⁵, Yuvaraj Singh⁶ and Deepan Dalal⁷, ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²Rhode island hospital, Brown University Warren Alpert School of Medicine, Providence, RI, ³Brown University School of Public Health, Providence, RI, ⁴Rhode island hospital, Brown University Warren Alpert School of Medicine, Seekonk, MA, ⁵Westerly Hospital, Yale New Haven Health, Westerly, RI, ⁶Saint Vincent Hospital, Worcester, MA, ⁷Brown University School of Medicine, Providence, RI
Background/Purpose: Depression is a common co-morbidity that has been shown to worsen symptoms such as pain, fatigue, decreased functional status, decreased disease remission, and response…
Abstract Number: 1771 • ACR Convergence 2022
The Effectiveness of a Treat-to-target Strategy in Rheumatic Diseases: A Systematic Literature Review and Meta-analysis
Yanjie Hao¹, Shereen Oon² and Mandana Nikpour³, ¹The University of Melbourne, Melbourne, Australia, ²The University of Melbourne Department of Medicine at St. Vincent’s Hospital Melbourne, Melbourne, Australia, ³The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: The concept of treat-to-target (T2T), a strategy in which treatment is directed to reach and maintain a defined goal such as remission or low…
Abstract Number: 1966 • ACR Convergence 2022
Favorable Effects of TNF Inhibitors on Intima Media Thickness and Arterial Stiffness in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Eva van Geel¹, Bafrin Abdulmajid¹, Annelies Blanken² and Michael Nurmohamed³, ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: Controlling inflammation with tumour necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients is hypothesized to reduce their cardiovascular risk. Arterial wall thickness (carotid…
Abstract Number: 1996 • ACR Convergence 2022
Individual Patient Data Meta-analysis on Continued Use of Glucocorticoids After Their Use as Bridging Therapy in Patients with Rheumatoid Arthritis
Lotte van Ouwerkerk¹, Patrick Verschueren², Pascal de Jong³, Paul Emery⁴, Josef Smolen⁵, Robert Landewé⁶, Willem Lems⁷, Maarten Boers⁸, Tom Huizinga¹, CF Allaart¹ and Sytske Anne Bergstra⁹, ¹Leiden University Medical Center, Leiden, Netherlands, ²University Hospital Leuven, Leuven, Belgium, ³ErasmusMC, Hendrik Ido Ambacht, Netherlands, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Medical University of Vienna, Vienna, Austria, ⁶Amsterdam University Medical Center, Meerssen, Netherlands, ⁷Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁹LUMC, Leiden, Netherlands
Background/Purpose: Short-term (< 3 months) treatment with glucocorticoids (GC) ("bridging") is recommended in the EULAR 2019 rheumatoid arthritis (RA) recommendations when starting a csDMARD in…
Abstract Number: 2016 • ACR Convergence 2022
Safety and Efficacy Associated with Long-Term Low Dose Glucocorticoids in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
Andriko Palmowski¹, Sabrina Mai Nielsen², Zhivana Boyadzhieva³, Abelina Schneider³, Anne Pankow³, Linda Hartman⁴, Jose Pereira da Silva⁵, John Kirwan⁶, Siegfried Wassenberg⁷, Christian Dejaco⁸, Robin Christensen⁹, Maarten Boers¹⁰ and Frank Buttgereit¹¹, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²The Parker Institute, Section for Biostatistics and Evidence-Based Research, Bispebjerg-Frederiksberg Hospital, Frederiksberg, Denmark, ³Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁴Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands, ⁵University of Coimbra, Rheumatology, Columbia, Portugal, ⁶University of Bristol, Bristol, United Kingdom, ⁷Rheumazentrum Ratingen, Ratingen, Germany, ⁸Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, and Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ¹⁰Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ¹¹Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany
Background/Purpose: There is ongoing controversy about the safety and efficacy of long-term low dose glucocorticoids (GCs) in rheumatoid arthritis (RA). Our aim was to study…
Abstract Number: 2123 • ACR Convergence 2022
Hierarchical Ranking of Biologic Disease-Modifying Antirheumatic Drugs and Targeted Systemic Therapies for Psoriatic Arthritis: A Network Meta-analysis
Jesus Diaz¹, Guillermo Quiceno² and Adela Castro³, ¹Hamilton Medical Center, Chattanooga, TN, ²UT Southwestern Medical Center, Dallas, TX, ³Hamilton Physician Group-Specialty Care, Dalton, GA
Background/Purpose: There are an increasing number of biological and targeted DMARDs in PsA. However, challenges around treatment selection remain, given the few head-to-head studies directly…
Abstract Number: 0141 • ACR Convergence 2022
Is Rituximab Associated with Worse Outcomes in COVID-19 Patients? A Meta-analysis
Yasmin Gerais¹, Chenyu Sun¹, Bethany King², Scott Lowe³, Biniyam Mohammed¹, Rachel Bentley³, Yaru Li⁴, Binyu Wei⁵ and Chuanhui Xu⁶, ¹Ascension Saint Joseph hospital, Chicago, IL, ²MercyOne Des Moines Medical center, Des Moines, IA, ³College of Osteopathic Medicine, Kansas City University, Kansas, MO, ⁴Swedish Hospital, Chicago, IL, ⁵Harvard Medical School, Boston, MA, ⁶Tan Tock Seng Hospital, Singapore, Singapore
Background/Purpose: Rituximab targets the CD20 antigen to deplete B cells and is indicated for a number of autoimmune diseases and other conditions. Accumulating data suggest…
Abstract Number: 2169 • ACR Convergence 2022
Cardiac Rhythm and Conduction Abnormalities in Systemic Sclerosis-meta-analysis
Drashti Antala¹, Angkawipa Trongtorsak¹, Qingqing Meng¹, Akshaya Ramachandran¹, Aanshi Patel², Pabitra Adhikari¹, Prasun Pudasainee¹ and Krutarth Pandya³, ¹Ascension Saint Francis hospital, Evanston, IL, ²B.J. Medical College, Ahmedabad, Ahmedabad, India, ³Trumbull Regional Medical Centre, Warren, OH
Background/Purpose: Systemic sclerosis( SSc) can primarily cause repeated focal ischaemic insults in the myocardium and result in irreversible myocardial fibrosis. Myocardial involvement, when becomes clinically…
Abstract Number: 0328 • ACR Convergence 2022
Predicting Progression from Undifferentiated to Definitive Connective Tissue Diseases: A Systematic Review and Meta-analysis
Sarah Dyball¹, Mia Rodziewicz¹, Claudia Mendoza Pinto², Ian N. Bruce³ and Ben Parker⁴, ¹The University of Manchester, Manchester, United Kingdom, ²Systemic Autoimmune Diseases Research Unit, High-Specialty Medical Unit-CIBIOR, Mexican Social Security Institute, Puebla, Mexico, ³Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ⁴Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom
Background/Purpose: Undifferentiated connective tissue disease (UCTD) encapsulates a broad range of conditions including incomplete forms of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), some…
Abstract Number: 0426 • ACR Convergence 2022
The Relative Efficacy of Biologic and Targeted Synthetic DMARDs in Ankylosing Spondylitis: A Network Meta-Analysis
Jesus Diaz¹, Guillermo Quiceno², Cathy Lee Ching³ and Adela Castro⁴, ¹Hamilton Medical Center, Chattanooga, TN, ²UT Southwestern Medical Center, Dallas, TX, ³University of Mississippi Medical Center, Jackson, MS, ⁴Hamilton Physician Group-Specialty Care, Dalton, GA
Background/Purpose: There is an unmet medical need for the treatment of patients with active ankylosing spondylitis (AS) who have an inadequate response to NSAIDs. Prior…
Abstract Number: 0484 • ACR Convergence 2022
Epidemiology and Predictors of Relapse in Giant Cell Arteritis: A Systematic Review and Meta-analysis
Lien Moreel¹, Albrecht Betrains¹, Geert Molenberghs², Steven Vanderschueren¹ and Daniel Blockmans¹, ¹University Hospitals Leuven, KU Leuven, Leuven, Belgium, ²KU Leuven, Leuven, Belgium
Background/Purpose: The aim of this study was to estimate the timing of relapse, the prevalence of multiple relapses and the predictors of relapse in patients…
Abstract Number: 0739 • ACR Convergence 2022
Effect of Tailored Self-Management Interventions on Health Outcomes in Individuals with Chronic Musculoskeletal Conditions
Ellen Wang¹, Isabel Rodrigues² and Linda Li³, ¹University of British Columbia, Arthritis Research Canada, Vancouver, BC, Canada, ²McMaster University, GERAS Centre for Aging Research, Hamilton, ON, Canada, ³University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Self-management, has been recognized as an essential component of successful chronic musculoskeletal (MSK) management; yet existing reviews of self-management interventions have found only modest…

« Previous Page
1
…
4
5
6
7
8
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].